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Introduction
Breast cancer (BC) is the most common malignancy 
among women, with a growing incidence. Every tenth pri-
mary cancer patient is diagnosed with breast cancer. It is also 
the leading cause of cancer death in women [1].
Breast cancer is a group of heterogeneous diseases with 
nu merous genetic alterations and relatively uniform histo-
logical phenotypes. Therefore, identification of the histologi-
cal char acteristics that can help to predict the therapeutic re-
sponse or the clinical prognosis in breast core needle biopsy 
(CNB) specimens can prove valuable [2].
Neoadjuvant chemotherapy (NAC) of BC improves out-
comes, especially in patients with locally advanced and in-
flammatory cancer. Further insight into clinic-pathological 
factors influencing outcomes is essential to define the optimal 
therapeutic strategy for each category of patients and to pre-
dict the response to the treatment [3].
Presently, preoperative core needle biopsy (CNB) is the 
gold standard procedure in cancer diagnostics. In addition to 
its diagnostic role, recent data have suggested another role for 
CNB in the analysis of predictive biomarkers, particularly uti-
lizing histomorphological characteristics [4].
In addition, significant volume reduction in tumors after 
neoadjuvant chemotherapy may permit subsequent, success-
ful breast-conserving surgical treatment [5].
There is significant variability in the histopathologic re-
sponse of tumors to neoadjuvant chemotherapy, with ap-
proximately 15% of patients achieving a complete response, 
whereas, at the other end of the spectrum, 15% of patients 
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Abstract
Backgraund: Breast cancer is one of the three most common cancers along with lung and colon cancer. It is a leading cause of cancer deaths in both 
developing and developed countries. Within 2 decades, neoadjuvant chemotherapy (NAC) has become a standard treatment option in breast cancer. 
Relevant articles were identified by means of PubMed, Embase, Web of Science, Cochrane Library and Springer Link databases published during the 
years 2010-2019, describing the role of molecular biomarkers in the assessment of NAC for breast cancer.
Conclusions: The size of the breast primary tumor, the affection of the regional lymph nodes, the degree of tumor differentiation, the expression of 
hormone receptors, HER2neu, ki67 serve as main criteria for predicting the response to NAC. Preoperative core needle biopsy is the gold standard 
procedure in cancer diagnostics, in the analysis of predictive biomarkers, particularly uti lizing histomorphological characteristics. Carrying out a larger 
number of cycles of NAC as well as correlating the schemes in relation to the immunohistochemical types have a direct influence on obtaining a good 
response to treatment. Patients with a pathologic complete response had superior survival outcomes compared with patients who had residual disease.
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display minimal change or progressive disease. Currently, 
the underlying mechanism for this variability is unknown. 
Contributing factors may include the diverse genetic back-
ground and hormonal environment of the tumor. Previous 
studies have focused on the correlation between the response 
of tumors to chemotherapy and various factors, such as histo-
logic grade, DNA ploidy, cell kinetics, and hormonal receptor 
status of the primary tumor. However, those studies yielded 
inconsistent results [6, 7, 8].
Therefore, despite the cumulation of more information 
about biomarker impact in breast cancer chemotherapy, 
mostly treatment regimens are standard, so the 5-year sur-
vival rate did not serve to make significant changes.
It was searched what the PubMed, Embase, Web of Science, 
Cochrane Library and Springer Link databases published 
during the years 2010-2019. The author identified relevant 
articles describing the role of molecular biomarkers in the 
assessment of neoadjuvant chemotherapy for breast cancer.
Discussion
The purpose of this review is to present the role of assess-
ing predictive molecular markers in selecting the chemother-
apeutic treatment needed for breast cancer patients.
NAC that is designed to be used before surgical removal of 
a tumor has attracted special attention in oncology [9].
The application of neoadjuvant chemotherapy in locally 
advanced breast cancers has demonstrated high efficacy by 
transforming inoperable tumors into operable, avoiding radi- 
cal mastectomies in ~ 25% [9].
The indications for NAC at present are quite broad: BC in 
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the early stages in preparation for organ-threatening opera-
tions, locally advanced BC, edema-inflammatory form of the 
disease, regional lymph nodes affection, and big size of the 
primary tumor [10].
There are several benefits of using neoadjuvant chemo-
therapy. It provides a unique opportunity to evaluate the re-
sponse to treatment with a complete pathological response 
that acts as a surrogate marker of survival and for a faster as-
sessment of the efficacy of new therapeutic agents and early 
cessation of ineffective treatment. In addition, in case of re-
sistance to treatment, dose adjustment and / or switching to 
another drug relieves patients of the burden of toxicity and 
side effects. NAC provides an opportunity for individualized 
therapy and allows the collection of tumor samples before, 
during, and after treatment for translational research [11]. 
A number of data have been published in the literature on 
the importance of applying long-term neoadjuvant chemo- 
therapy in cases of chemoresistant breast cancer [12, 13, 14].
The appearance of chemoresistance of primary breast tu-
mors is of primordial importance in the modern treatment of 
BC. The theoretical-practical aspects that clarify the acquisi-
tion of cancer cell resistance to chemotherapeutic drugs are 
insufficiently studied in the literature. Various theories are 
assumed by which the gene encoding the transport protein 
of chemotherapeutic drugs is disrupted, the genetic modifica-
tion of the receptors of the cancer cell membrane, the changes 
of intracellular transport, etc. Thus, the study of the predic-
tive factors of the appearance of chemotherapeutic resistance 
is of great importance in the evaluation of individualized drug 
treatment schemes [15].
The response rate of the tumor to NAC can be evaluated 
by several methods: clinical examination (assessment of tu-
mor size, skin changes and peritumoral regions), breast im-
aging (ultrasound, mammography, MRI), postoperative mor-
phopathological examination. Particular attention is paid to 
the assessment of the degree of pathomorphosis in the post-
operative histopathological examination, the assessment of 
morphological changes of the tumor and peritumoral region, 
the assessment of tumor cellularity [16].
The response to NAC is assessed by changing the size of 
the primary tumor and the affected lymph nodes in the pre- 
and post-treatment phase. There are 3 types of response to 
NAC in the literature: pathologic complete response (PCR), 
near complete response (NCR) defined by the presence of 
residual primary tumor < 1 cm3, partial pathologic response 
(PPR) defined by the presence of residual primary tumor 
measuring > 1 cm3 [8].
In cases with PCR, the authors mention a better prognosis 
[17].
Studies have shown a response rate to NAC with a varia-
tion between 20-30% depending on the immunogenetic pro-
file and the chemotherapeutic scheme used [18].
Achieving complete and partial remission of NAC has bet-
ter long-term results, with better overall survival compared to 
cases where tumors do not respond to therapy [19].
Several studies have shown that the immuno-genetic pro-
file of the tumor can serve as a primary criterion in assessing 
the rate of subsequent response to treatment. Triple-negative 
and HER2neu-positive tumors (with hormone-negative re-
ceptors) are more aggressive and serve as a criterion for per-
forming NAC. The best response to NAC is found in tumors 
with small size, high degree of differentiation, the presence of 
tumor necrosis, hormone-negative receptors, the presence of 
HER2neu receptor positivity [20, 21].
Luminal type A, compared to other immunohistochemi-
cal types, has a better prognosis and in most cases does not 
require neoadjuvant treatment. The rate of PCR after NAC in 
the case of Luminal A type is 6%, compared to Luminal B – 
10%, Her2neu – 47%, Basal-type – 37% [18, 22, 23].
Total and breast PCR rates were higher in HR negative 
(HR−) patients (26% and 32%, respectively) than in HR posi-
tive (HR+) patients (4% and 7%, respectively). Compared 
to HR+ patients, HR− patients had higher recurrence rates 
(38% versus 22%). Human epidermal growth factor recep-
tor 2 positive patients treated with neoadjuvant trastuzumab 
(NAT) demonstrated higher total PCR (34% versus 13%), 
breast PCR (37% versus 17%), and nodal PCR rates (47% ver-
sus 23%) compared to HER2+ patients not treated with NAT. 
Furthermore, HER2+ patients who received NAT had lower 
recurrence rates (5% versus 42%) and increased overall sur-
vival (97% versus 68%) [18].
Zhang and co-authors noticed that HER2+ patients have 
poor response to neoadjuvant chemotherapy with 5-fluoro-
uracil, doxorubicin, cyclophosphamide (FAC) [17]. 
So, Transtuzumab, humanized anti-HER2 monoclonal 
antibody, is considered to be first-line treatment for the pa-
tients with HER positive Breast Cancer [2, 17].
The Ki67 index also plays an important role in assessing 
the need for NAC performance. Some authors have evaluated 
the higher efficacy of NAC in cases with high Ki67 [15].
NAC cannot modify the molecular subtype of the tumor. 
Changing the status of receptors after neoadjuvant chemo-
therapy does not show any change in the cellular origin of the 
tumor [24].
The histological grade of the CNB specimen represents 
the significant predictors of chemotherapeutic response us-
ing  the percentage of the area occupied by the tumor infil-
trating lymphocytes (TILs), retraction artifact status, small 
cell-like feature status, level of tumor necrosis, and clear cyto-
plasm status [4].
The authors mention a directly proportional correlation. 
The higher grade of differentiation has the better response 
rate to NAC. Histologically low differentiated tumors have 
a lower response rate to NAC. The degree of pathomorpho-
sis is the main indicator of the response to NAC. Usually the 
absence of response correlates directly with the first grade of 
pathomorphosis, while the fourth grade of pathomorphosis 
correlates directly with PCR [4, 15, 23].
The assessment of the prognosis depending on the chang-
es of the tumor biomarkers serves an important criterion in 
establishing the subsequent medical conduct of this patient. 
The change in the status of hormone receptors after per-
forming NAC, from negative to positive, is interpreted as a 
favorable indicator of disease prognosis. The change in Her2 
status from positive to negative confirms the efficacy of NAC 
and good prognosis of the disease. The absence of response 
to NAC in cases of Her2-positive and triple-negative tumors 
serves as an unfavorable prognostic factor [20, 25].
70
ReVIeW ARTIcLeV. Cucieru. Moldovan Medical Journal. March 2021;64(1):68-70
Randomized prospective studies are needed to select a 
more balanced choice of patient characteristics and treat-
ment schemes at the beginning and to evaluate the treatment 
response more appropriately.
Conclusions
1. The size of the breast primary tumor, the affection of 
the regional lymph nodes, the degree of tumor differentia-
tion, the expression of hormone receptors, HER2neu, ki67 
serve as main criteria for predicting the response to neoad-
juvant chemotherapy.
2. Preoperative core needle biopsy (CNB) is the gold 
standard procedure in cancer diagnostics, in the analysis of 
predictive biomarkers, particularly uti lizing histomorpho-
logical characteristics.
3. Carrying out a larger number of cycles of neoadjuvant 
chemotherapy as well as correlating the schemes in relation 
to the immunohistochemical types have a direct influence 
on obtaining a good response to treatment.
4. Patients with a PCR had superior survival outcomes 
compared with patients who had residual disease.
5. The standardization and improvement of methods to 
assess the response to induction chemotherapy are sorely 
needed.
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